Press & Media

Last Updated: May 2026

Telehealth FX provides journalists, researchers, and media outlets with expert clinical commentary, market analysis, and educational resources regarding the rapidly evolving GLP-1, compounding, and telehealth industries.

Media Inquiries & Expert Commentary

Our clinical contributors and healthcare analysts are available for interviews, background briefings, and commentary on:

• The post-shortage FDA regulatory landscape under Section 503A and 503B of the FD&C Act.
• Comparative clinical efficacy between Semaglutide, Tirzepatide, and next-generation multi-agonists.
• Direct-to-consumer telehealth pricing dynamics and cash-pay market trends.
• Hormone optimization, TRT regulatory updates, and telemedicine compliance.

Media Contact

For press inquiries, expert quotes, or media kit requests, please contact our press relations department at [email protected]. We prioritize media inquiries and typically respond within 4 business hours.